What Is the Treatment of Drug-induced Myopathy?
Drug-induced myopathy (ICD G72.0 / 8C80) presents with myalgia and muscle weakness attributable to a pharmacological agent. The first clinical priority is identifying and addressing the causative exposure before any additional measures are considered.
Clinical Goals
- Resolution of myalgia and muscle weakness
- Normalization of creatine kinase activity
Treatment Approach
First-line management centres on removing the offending agent. Alongside that, a range of symptomatic measures — physical and pharmacological — may be applied to support recovery.
The complete sequenced regimen, including specific symptomatic options and decision criteria, is available in the structured protocol below.
References
DOI: 10.3390/biomedicines12050987
- Discontinuation of potentially causative medications
- Symptomatic treatment (warm compresses, rest, analgesics, NSAIDs, myorelaxants, physiotherapy)
- In the vast majority of patients, mild muscle symptoms resolve after discontinuation of drugs.
- Withdrawal of the drug results in the resolution of symptoms and normalization of muscle laboratory parameters.
View source ↗